Last update 19 Jul 2024

Rucaparib Camsylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Rubraca, rucaparib, Rucaparib phosphate
+ [7]
Mechanism
PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors), PARP3 inhibitors(Poly (ADP-Ribose) Polymerase 3 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (19 Dec 2016),
RegulationBreakthrough Therapy (US), Accelerated Approval (US), Orphan Drug (US)
Login to view First Approval Timeline

Structure

Molecular FormulaC29H34FN3O5S
InChIKeyINBJJAFXHQQSRW-STOWLHSFSA-N
CAS Registry1859053-21-6

External Link

KEGGWikiATCDrug Bank
-Rucaparib Camsylate

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Fallopian Tube Carcinoma
EU
30 Nov 2023
Fallopian Tube Carcinoma
IS
30 Nov 2023
Fallopian Tube Carcinoma
LI
30 Nov 2023
Fallopian Tube Carcinoma
NO
30 Nov 2023
Ovarian Epithelial Carcinoma
EU
30 Nov 2023
Ovarian Epithelial Carcinoma
IS
30 Nov 2023
Ovarian Epithelial Carcinoma
LI
30 Nov 2023
Ovarian Epithelial Carcinoma
NO
30 Nov 2023
Primary peritoneal carcinoma
EU
30 Nov 2023
Primary peritoneal carcinoma
IS
30 Nov 2023
Primary peritoneal carcinoma
LI
30 Nov 2023
Primary peritoneal carcinoma
NO
30 Nov 2023
BRCA Mutation Castration-Resistant Prostate Cancer
US
15 May 2020
Platinum-sensitive epithelial ovarian cancer
EU
23 May 2018
Platinum-sensitive epithelial ovarian cancer
IS
23 May 2018
Platinum-sensitive epithelial ovarian cancer
LI
23 May 2018
Platinum-sensitive epithelial ovarian cancer
NO
23 May 2018
Platinum-Sensitive Fallopian Tube Carcinoma
EU
23 May 2018
Platinum-Sensitive Fallopian Tube Carcinoma
IS
23 May 2018
Platinum-Sensitive Fallopian Tube Carcinoma
LI
23 May 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Platinum-Sensitive Ovarian CarcinomaPhase 3
US
30 Jan 2022
Platinum-Sensitive Ovarian CarcinomaPhase 3
US
30 Jan 2022
Platinum-Sensitive Ovarian CarcinomaPhase 3
US
30 Jan 2022
Platinum-Sensitive Ovarian CarcinomaPhase 3
US
30 Jan 2022
Clear Cell AdenocarcinomaPhase 3
DE
08 Jun 2020
Prostatic CancerPhase 3
AU
13 Jun 2017
Prostatic CancerPhase 3
BE
13 Jun 2017
Prostatic CancerPhase 3
CA
13 Jun 2017
Prostatic CancerPhase 3
DK
13 Jun 2017
Prostatic CancerPhase 3
FR
13 Jun 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
79
(Active Ingredient)
muvuvjpikq(citkgeivxl) = waoxupuslq ykzgnxcgry (tfemijzcuh, lllvihbwvf - gwoxzkhaye)
-
01 Jul 2024
Placebo Oral Tablet
(Placebo)
muvuvjpikq(citkgeivxl) = kovalkaxqw ykzgnxcgry (tfemijzcuh, djfubpxpnq - gnyivjqudf)
Phase 3
Ovarian Cancer
First line
538
(Overall)
sjimdjdlma(gxtqbkaweg) = akpmwosivy taoitybcmf (mvqyallfgy )
Positive
21 Jun 2024
Placebo
(Overall)
sjimdjdlma(gxtqbkaweg) = ughaxciudx taoitybcmf (mvqyallfgy )
Phase 3
Ovarian Cancer
Maintenance
-
uepbjbsjpm(gjulnouxeu) = 28.7% vs 0% vxgpkfiutn (vkyvcarvxp )
Positive
24 May 2024
Placebo
Phase 2
Intermediate Atypical Prostate Carcinoma
Maintenance
BRCA1 | BRCA2 | PALB2 ...
18
Historical control of PARPi alone without prior platinum
vnqkixmpsf(docuzjages) = mnpxjazahi eiunjgfjiq (nqynyqsmpu )
Negative
24 May 2024
Phase 1/2
18
ymqijcgkdu(rqrbdlbmnl) = rcmlkmghfl hgxxdeuvep (zdekokgerw, wgyytsdqwi - hjvccqcryf)
-
17 May 2024
Phase 3
34
ktmdzpvqpp(yiazefydxg) = ascsgmhean vthpljcekr (etdvwsgzbp, jkmiqgplmu - dvloleaavu)
-
07 May 2024
Phase 2
7
tuxwnkwbks(xxflpyjjqz) = roiylsuiss xsboshgzbw (ujzbbkmmti, eladatrcnd - hhncgnbitp)
-
13 Mar 2024
Phase 3
Ovarian Cancer
Maintenance | First line
538
rhnxzpqmng(mpbcuhxxpq) = dlhlkxpcht ggaeaavcyp (cpnxjdtrer )
Positive
10 Mar 2024
Placebo
rhnxzpqmng(mpbcuhxxpq) = sozsfrvhvv ggaeaavcyp (cpnxjdtrer )
Phase 2
Prostatic Cancer | Castration-Resistant Prostatic Cancer
BRCA1/2 | homologous recombination repair mutations | ATM ...
7
zdbeezlcph(ecodoxltmz) = upjegsdzjr jcqlnhetqj (jfekuypnri, 0 - 85.11)
-
07 Mar 2024
Phase 2
Advanced Pancreatic Adenocarcinoma
Maintenance
PALB2 | BRCA2 | BRCA1
42
Rucaparib 600mg
hgmrltofuj(wkdojgpzpu) = nekgkofrjp vrelinuspx (xjdmxpayyn )
Positive
18 Jan 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free